Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Poch, David
• Is Part Of: BMC pulmonary medicine. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 4
• Publication Date: 2016-12
• Subjects: Pulmonary arterial hypertension -- sGC stimulators -- Cyclic guanosine monophosphate -- Chronic thromboembolic pulmonary hypertension; Lungs -- Diseases -- Periodicals; 616.24005
• DOI: 10.1186/s12890-016-0229-x
• Languages: English
• ISSNs: 1471-2466

Abstract

Abstract Background We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications. Case presentation A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy. Conclusion This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy.